Biocracked
**Approach 1 (macro science), Palette D (bold color field).**

Extreme close-up microscopy-style photograph of a cluster of fat cells (adipocytes), rendered as translucent, pearly spheres with thin membranes and tiny lipid droplets inside. One cell in the center is visibly shrinking and blebbing, its membrane crinkled and fragmenting into small beads, the look of apoptosis. A few of the surrounding cells are intact and glossy. The cells sit against a saturated tomato-red backdrop, so the pale yellow-cream spheres stand out sharply. The camera looks straight down at shallow depth of field, with the focal plane on the dying cell and the edges softly blurred. Soft, diffuse top light gives gentle highlights and warm shadows, with no blue cast. One thin electric green fluorescent ring around the central cell's nucleus is the only green accent. The mood is analytical, precise and quietly skeptical.
Research

How does CBL-514 work? Here's the science

Dr. Synapse · · 5 min read

How does CBL-514 work? Here's the science

The interesting claim about CBL-514 is not that it "melts" fat. The claim is that it nudges fat cells toward programmed cell death, a process called apoptosis, inside the area where it is injected. That distinction shapes everything else about the compound: what it is supposed to do, what researchers measured, and what the evidence does and does not show.

A note on naming: the compound is CBL-514, not "CL-514". It is an investigational small-molecule injectable from Caliway Biopharmaceuticals (New Taipei City, Taiwan). It is not a supplement, not an oral pill, and not an approved consumer product. In the research discussed here, investigators in a clinical trial gave it as subcutaneous injections into abdominal fat.

The molecular claim: DYRK1b, caspase 3, and Bax/Bcl-2

The 2025 Phase 2 paper describes CBL-514 as "a small-molecule injection lipolysis agent that promotes adipocyte apoptosis and targeted subcutaneous fat reduction in nonclinical studies." The more specific mechanism comes from the earlier Phase 2a paper (Goodman et al., 2022). It states that nonclinical studies showed CBL-514:

  • inhibits DYRK1b, a cell-survival kinase;
  • upregulates the apoptosis mediators caspase 3 and Bax/Bcl-2; and
  • induces dose-dependent adipocyte apoptosis in vitro and in vivo.

The Phase 2a paper also reports lipolysis in vitro and reduced subcutaneous adiposity in targeted areas in animal studies.

In plain terms, the proposal is that the drug interferes with a survival signal in fat cells and tips the balance toward the cell's own death machinery. Caspase 3 is a key executioner enzyme in apoptosis. The Bax/Bcl-2 balance is a standard readout of whether a cell is leaning toward death or survival.

What we don't know

There are important caveats. These nonclinical findings are cited to unpublished, confidential Caliway reports, so they are company-reported and not independently detailed in the Phase 2 paper's methods. The published papers also do not disclose the chemical structure of CBL-514. Without that, nobody outside the company can say what the molecule is, how it binds DYRK1b, or whether DYRK1b inhibition is the whole story.

Local fat-cell death, not a metabolic boost

The proposed mechanism is not about raising metabolic rate or increasing whole-body energy expenditure. The strategy is local: inject into abdominal subcutaneous fat, trigger fat-cell death there, and look for a measurable drop in fat thickness and volume on ultrasound.

The Phase 2 trial's weight data fit that framing. Mean body-weight change was minimal: +0.45 kg at the 4-week follow-up and +0.02 kg at 8 weeks in the CBL-514 group, versus -0.76 kg and -0.26 kg with placebo. The authors report no significant changes in mean weight or BMI, and they say localized fat loss occurred even in some participants who gained more than 1 kg (data not shown). This is a local fat-volume story, not a weight-loss story.

What the human trial measured

The Phase 2 study (Gold et al., Aesthetic Surgery Journal, 2025) was randomized, single-blind, and placebo-controlled, run at five centers in the United States and Australia. Participants received up to four treatments at 4-week intervals. Each injection delivered 2.4 mL of CBL-514 at 2 mg/cm², up to 600 mg per treatment, or saline placebo. Fat volume was estimated from ultrasound thickness at four scan points multiplied by a defined 300 cm² treatment area.

The authors report that the trial met its primary endpoint. In the intention-to-treat analysis, 63.9% of CBL-514 participants (23/36) had at least 150 mL fat-volume loss at the 4-week follow-up, versus 17.4% (4/23) with placebo. At 8 weeks the figures were 69.6% (16/23) versus 0.0% (0/16). Least-squares mean change from baseline in the CBL-514 group was -199.80 mL at 4 weeks and -209.46 mL at 8 weeks.

Those are the outcomes. They are not mechanism evidence. The trial measured volume, thickness, photographs, and safety. It did not present human biopsy or caspase data, so nothing in the paper shows that DYRK1b inhibition or adipocyte apoptosis occurred in the people treated. The human data show that fat thickness on ultrasound fell. The apoptosis explanation remains a hypothesis carried over from nonclinical work.

Reading the results with caution

Several limitations matter for anyone weighing the mechanism story:

  • Single-blind only. Participants were blinded, but investigators, site staff, and the sponsor were not.
  • High dropout. Of 75 treated participants, 37 (49.3%) did not complete the study. Denominators shrank at each follow-up, and the per-protocol population was only 30 people.
  • Sponsor involvement. Caliway took part in study design, data collection and analysis, interpretation, writing, and the decision to submit.
  • Exploratory sample size and no adjustment for multiple testing.
  • Participants were mostly women (94.0% in the CBL-514 group).

The authors say results are "comparable to that achieved with liposuction" and that the trend "appears to be larger" than in some cryolipolysis studies. These are the authors' interpretations. Measurement methods differed, and there was no head-to-head comparison.

How this differs from ATX-101

The only FDA-approved injectable for fat reduction mentioned in the paper is ATX-101 (deoxycholic acid, Kybella), approved only for submental (under-chin) fat. That drug works through adipocytolysis, a different framing from CBL-514's proposed programmed cell death, and the papers raise tissue-selectivity concerns about it. CBL-514 is described as promoting targeted fat reduction without skin necrosis, ulceration, or nerve injury in nonclinical work. The Phase 2 authors report none of those events in their trial.

That is an observation from one mid-stage study, not proof of a long-term safety advantage. The trial was small, had substantial attrition, and was not designed to settle comparative safety questions.

Bottom line

CBL-514's proposed mechanism is specific: inhibit DYRK1b, upregulate caspase 3 and Bax/Bcl-2, and drive dose-dependent adipocyte apoptosis in the treated area. The human data show a local ultrasound-measured fat reduction versus placebo. The link between the two has not been shown in people, and the molecular evidence comes from unpublished company reports. CBL-514 remains investigational, and this article is not guidance for use.

Sources

More from this CBL-514 series

This article is part of our CBL-514 series. For the full Phase 2 trial overview, start here: CBL-514 Injection Lipolysis: A Phase 2 Map of the Evidence.

Original study

Read the original research on pmc.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 1, macro science, with Palette D, bold color field.

Extreme close-up microscopy-style photograph of a cluster of adipocytes (fat cells). Each is a translucent, pale yellow sphere with a thin membrane, and a few are shrunken and crinkled to suggest apoptosis. The cells sit against a saturated magenta backdrop. The camera is slightly above, at a shallow 30-degree angle, with a very shallow depth of field so the foreground cells are razor sharp and the rest melts into soft bokeh. Hard, clean side light from the left makes the membranes glisten and casts crisp magenta-tinted shadows. One tiny electric green fluorescent speck glows inside a single collapsing cell as a subtle accent. The mood is precise, clinical and curious, with a bold editorial feel. There is no text and no blue cast.
research

CBL-514 Injection Lipolysis: A Phase 2 Map of the Evidence

BY DR. SYNAPSE ·

CBL-514 is an investigational injection that aims to trigger fat-cell apoptosis in a treated abdominal area. In a 2025 Phase 2 trial of 76 randomized participants, it produced large ultrasound-measured fat-volume losses versus saline while mean body weight stayed flat. This hub maps the design, the 2 mg/cm² dosing, the exact efficacy figures with their shrinking denominators, and the company-reported DYRK1b/caspase mechanism. It also spells out the caveats: single-blind design, sponsor involvement, about 49% non-completion, short follow-up and a mostly female sample. Five deeper explainers are linked for readers who want to go further.

Approach 2, lab in action, with palette D, bold color field.

Straight-on, slightly elevated close shot of a gloved hand in a pale nitrile glove holding a glass syringe with a fine needle. The syringe is filled with clear liquid and sits over a row of small glass vials in a matte white rack. The whole scene sits against a saturated tomato-red seamless backdrop. Soft, even studio light gives crisp highlights along the syringe barrel and the vial glass, plus gentle warm-red reflections on the surfaces. A thin electric green (#00e676) cap on one vial is the only small accent. The dosing markings on the syringe are blurred and unreadable. Shallow depth of field blurs the back vials into soft shapes. The mood is precise, clinical and investigational, with high contrast and a measured, careful feel. No text, no labels, no logos.
research

CBL-514 Dosages - what does science say?

BY DR. SYNAPSE ·

CBL-514 trials are investigational injection protocols, and the "600 mg" figure is a per-treatment cap, not a supplement dose. This article walks through the Phase 2a dose-finding study (1.2, 1.6 and 2.0 mg/cm² over 150 cm², n=43, open-label) and explains where the much-quoted 24.96% figure comes from. It then covers the placebo-controlled Phase 2, which kept 2.0 mg/cm² but doubled the area to 300 cm² and raised the cap to 600 mg. You will see why mg totals cannot be compared across studies, what safety was reported, and why this is still not approved or advice.

Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
research

Does CBL-514 really burn fat? Here's what we know

BY HELIX WARD ·

The 2025 Phase 2 CBL-514 trial did not test weight loss. It tested whether an abdominal injection could cut at least 150 mL of subcutaneous fat volume on ultrasound, and 69.6% (16/23) of treated participants got there at 8 weeks versus 0/16 on placebo. But mean body weight did not fall (+0.02 kg), nearly half of treated participants did not complete the study, and the per-protocol group was just 30 people. Injection-site reactions were common, including discoloration in 71.4% and severe pain in 18.4%. Here is the data-first breakdown of what the trial shows and what it doesn't.

Approach 1, macro science, in palette D, bold color field.

Extreme close-up photograph of a cluster of fat cells (adipocytes) in tissue, shot like a stained microscopy image. Rounded, translucent, pearly-yellow lipid-filled cells press together in a honeycomb. Several in the center look collapsed and shriveled, with ruptured membranes and scattered droplets. A few fine threads of electric green (#00e676) fluorescent stain outline the cell walls. The camera is straight-on at shallow depth of field, with the background cells melting into soft blur. Bright, even transmitted light makes the membranes glow. The backdrop is a saturated magenta-to-tomato-red field that sets off the pale yellow cells. The mood is scrutinizing, skeptical and precise. No text, no labels.
research

CBL-514 fat removal injections: What does the science say?

BY DR. SYNAPSE ·

CBL-514 now has a placebo-controlled Phase 2 randomized trial in Aesthetic Surgery Journal, and the authors report it met its primary and secondary endpoints. But this appraisal shows why the design deserves a hard look: it was single-blind with unblinded investigators and sponsor, and the sponsor helped design, analyze and write the study. Of 75 treated participants, only 38 finished, and the per-protocol set was just 30 people. Follow-up ended 8 weeks after the final treatment, and the sample was mostly female and White. Here is what the trial can support, what it cannot, and why it is not medical advice or proof of an approved treatment.

This page is available in